Diabetic Foot Ulcers Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025

Published: Jul 2021

Pages: 120

SKU: IRTNTR45679

Snapshot

The diabetic foot ulcers therapeutics market share is expected to increase by USD 1.74 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 7.01%.

This diabetic foot ulcers therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers diabetic foot ulcers therapeutics market segmentation by product (ischemic and neuro-ischemic ulcer therapeutics and neuropathic ulcer therapeutics) and geography (North America, Europe, Asia, and ROW). The diabetic foot ulcers therapeutics market report also offers information on several market vendors, including 3M Co., Baxter International Inc., ConvaTec Group Plc, Dr. Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., Smith and Nephew plc, and Viatris Inc. among others.

What will the Diabetic Foot Ulcers Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Diabetic Foot Ulcers Therapeutics Market Size for the Forecast Period and Other Important Statistics

Diabetic Foot Ulcers Therapeutics Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The strong drug development pipeline is notably driving the diabetic foot ulcers therapeutics market growth, although factors such as the impact of complex pathogenesis in clinical trial design may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the diabetic foot ulcers therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Diabetic Foot Ulcers Therapeutics Market Driver

The strong drug development pipeline is one of the key drivers supporting the diabetic foot ulcers therapeutics market growth. The number of pipeline molecules for the treatment of diabetic foot ulcers is increasing at a significant pace. As of 2019, there were over ten different therapeutics undergoing various stages of clinical trials. The number of clinical trials is growing at a high rate. For instance, as of November 2020, Microbion Corp. is significantly focusing on the development of its potential candidate, MBN-101, which is currently in the pipeline. The drug has the potential to show dual broad-spectrum antimicrobial and anti-biofilm effects. Similarly, Oneness Biotech and ANTEROGEN are developing drugs for the treatment of diabetic foot ulcers. On obtaining regulatory approval, the molecules of these companies are likely to generate high revenue. Such developing factors will drive market growth during the forecast period.

Key Diabetic Foot Ulcers Therapeutics Market Trend

Increasing wound healing therapeutics is another factor supporting the diabetic foot ulcers therapeutics market growth. Wound healing occurs in four phases, including hemostasis, inflammatory, proliferative, and maturation. Various organizations are developing wound healing therapeutics for diabetic foot ulcers. For instance, ProNOx1 is in the Phase II stage of development by Edixomed for the treatment of diabetic foot ulcers. In addition, SER190 is under development by Serodus. It is in the preclinical stage of development for the treatment of diabetic foot ulcers. Wound healing therapeutics are likely to increase in number during the forecast period. This will contribute a major share of revenue to the global diabetic foot ulcers therapeutics market.

Key Diabetic Foot Ulcers Therapeutics Market Challenge

The impact of complex pathogenesis in clinical trial design is one of the factors hindering the diabetic foot ulcers therapeutics market growth. Diabetic foot ulcers are caused by numerous factors, such as peripheral neuropathy, structural foot deformity, and infection. Neuropathy and peripheral artery disease are associated with a high risk of developing foot ulcers. In addition, trauma is one of the main triggers. These complications can sometimes delay the healing process, which may ultimately lead to more complexities in treatment. The complexity of mechanisms involved in trials and related interventions determines the success of a trial. However, these interventions are mainly directed to certain defects in the foot care process. Failure of such trials and interventions due to their complexities will likely pose a challenge to the global diabetic foot ulcers therapeutics market during the forecast period.

This diabetic foot ulcers therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the diabetic foot ulcers therapeutics market as a part of the pharmaceutical market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the diabetic foot ulcers therapeutics market during the forecast period.

Who are the Major Diabetic Foot Ulcers Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

This statistical study of the diabetic foot ulcers therapeutics market encompasses successful business strategies deployed by the key vendors. The diabetic foot ulcers therapeutics market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

3M Co - The product is an antimicrobial wound gel that uses non-toxic technology for the deconstruction of the bacterial biofilm, extracellular polymeric substance matrix, kills bacteria, and defends from recolonization at the wound site.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The diabetic foot ulcers therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Diabetic Foot Ulcers Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the diabetic foot ulcers therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the pharmaceutical market includes the following core components:

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Which are the Key Regions for Diabetic Foot Ulcers Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

38% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for diabetic foot ulcers therapeutics market in North America. Market growth in this region will be slower than the growth of the market in Asia.

The rise in the prevalence of diabetes in the US will facilitate the diabetic foot ulcers therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, owing to the outbreak of the COVID-19 pandemic, the market is witnessing a slowdown in revenue growth. However, the market is slowly expected to witness recovery during 2021-2024, owing to growing efforts from the government to boost economic growth and resume normal operations across commercial sectors during the forecast period.

What are the Revenue-generating Product Segments in the Diabetic Foot Ulcers Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The diabetic foot ulcers therapeutics market share growth by the ischemic and neuro-ischemic ulcer therapeutics segment will be significant during the forecast period. Ischemic ulcers are likely to occur due to inadequate blood flow in various parts of the body. Neuro-ischemic ulcers take a long time to heal and often lead to limb amputation. According to the US NIDDK, 35%-45% of diabetic foot ulcers are caused by neuropathic and ischemic factors. Ischemic ulcers are responsible for about 1 out of every four hospital admissions among patients with diabetes globally. The global neuro-ischemic and ischemic ulcer therapeutics market is likely to be driven by the increasing prevalence of the disease and the rising number of awareness programs. These factors will propel the market growth during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the diabetic foot ulcers therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

Diabetic Foot Ulcers Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 7.01%
Market growth 2021-2025	$ 1.74 billion
Market structure	Fragmented
YoY growth (%)	6.60
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 38%
Key consumer countries	US, UK, Germany, China, and Canada
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	3M Co., Baxter International Inc., ConvaTec Group Plc, Dr. Reddys Laboratories Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., Smith and Nephew plc, and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Diabetic Foot Ulcers Therapeutics Market Report?

CAGR of the market during the forecast period 2021-2025
Detailed information on factors that will drive diabetic foot ulcers therapeutics market growth during the next five years
Precise estimation of the diabetic foot ulcers therapeutics market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the diabetic foot ulcers therapeutics industry across North America, Europe, Asia, and ROW
A thorough analysis of the market's competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of diabetic foot ulcers therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Table of Contents

***1. Executive Summary

***2. Market Landscape

**2.1 Market ecosystem

*Exhibit 01: Parent market

**2.2: Market Characteristics

**2.3 Value chain analysis

*Exhibit 02: Value chain analysis- Pharmaceuticals

*2.3.1 R&D and drug discovery

*2.3.2 Integration and product development

*2.3.3 Manufacturing

*2.3.4 Outbound logistics

*2.3.5 Marketing and sales

*2.3.6 Support services

*2.3.7 Innovation

***3. Market Sizing

**3.1 Market definition

*Exhibit 03: Offerings of vendors included in the market definition

**3.2 Market segment analysis

*Exhibit 04: Market segments

**3.3 Market size 2020

**3.4 Market outlook: Forecast for 2020 - 2025

*Exhibit 05: Global - Market size and forecast 2019 - 2024 ($ million)

*Exhibit 06: Global- Market size and forecast 2019-2024 ($ million), exclusive of COVID-19 impact

*Exhibit 07: Global market: Year-over-year growth 2019 - 2024 (%)

***4. Five Forces Analysis

**4.1 Five Forces Summary

*Exhibit 08: Five forces analysis 2020 & 2025

**4.2 Bargaining power of buyers

**4.3 Bargaining power of suppliers

**4.4 Threat of new entrants

**4.5 Threat of substitutes

**4.6 Threat of rivalry

**4.7 Market condition

*Exhibit 09: Market condition - Five forces 2019

***5. Market Segmentation by Product

**5.1 Market segments

*The segments covered in this chapter are:

Ischemic and neuro-ischemic ulcer therapeutics
Neuropathic ulcer therapeutics

*Exhibit 10: Product - Market share 2019-2024 (%)

**5.2 Comparison by Product

*Exhibit 11: Comparison by Product

**5.3 Ischemic and neuro-ischemic ulcer therapeutics - Market size and forecast 2019-2024

*Exhibit 12: Ischemic and neuro-ischemic ulcer therapeutics - Market size and forecast 2019-2024 ($ million)

*Exhibit 13: Ischemic and neuro-ischemic ulcer therapeutics - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact

*Exhibit 14: Ischemic and neuro-ischemic ulcer therapeutics - Year-over-year growth 2019-2024 (%)

**5.4 Neuropathic ulcer therapeutics - Market size and forecast 2019-2024

*Exhibit 15: Neuropathic ulcer therapeutics - Market size and forecast 2019-2024 ($ million)

*Exhibit 16: Neuropathic ulcer therapeutics - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact

*Exhibit 17: Neuropathic ulcer therapeutics - Year-over-year growth 2019-2024 (%)

**5.5 Market opportunity by Product

*Exhibit 18: Market opportunity by Product

***6. Customer landscape

**6.1 Customer landscape

*Exhibit 19: Customer landscape

***7. Geographic Landscape

**7.1 Geographic segmentation

*Exhibit 20: Market share by geography 2019-2024 (%)

**7.2 Geographic comparison

*Exhibit 21: Geographic comparison

**7.3 North America - Market size and forecast 2019-2024

*Exhibit 22: North America - Market size and forecast 2019-2024 ($ million)

*Exhibit 23: North America - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact

*Exhibit 24: North America - Year-over-year growth 2019-2024 (%)

**7.4 Europe - Market size and forecast 2019-2024

*Europe - Market size and forecast 2019-2024 ($ million)

*Exhibit 25: Europe - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact

*Exhibit 26: Europe - Year-over-year growth 2019-2024 (%)

**7.5 Asia - Market size and forecast 2019-2024

*Exhibit 27: Asia - Market size and forecast 2019-2024 ($ million)

*Exhibit 28: Asia - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact

*Exhibit 29: Asia - Year-over-year growth 2019-2024 (%)

**7.6 ROW - Market size and forecast 2019-2024

*Exhibit 30: ROW - Market size and forecast 2019-2024 ($ million)

*Exhibit 31: ROW - Market size and forecast 2019-2024 ($million), exclusive of COVID-19 impact

*Exhibit 32: ROW - Year-over-year growth 2019-2024 (%)

**7.7 Key leading countries

*Exhibit 33: Key leading countries

**7.8 Market opportunity by geography

*Exhibit 34: Market opportunity by geography ($ million)

***8. Drivers, Challenges, and Trends

**8.1 Market drivers

*8.1.1 Strong drug development pipeline

*8.1.2 Increasing incidence of diabetic foot ulcers

*8.1.3 Rising number of diabetes awareness programs

**8.2 Market challenges

*8.2.1 Impact of complex pathogenesis in clinical trial design

*8.2.2 High entry barriers

*8.2.3 Poor wound care management

**8.3 Market trends

*8.3.1 Increasing wound healing therapeutics

*8.3.2 Increased outsourcing of non-core activities

*8.3.3 Increase in R&D activities

***9. Vendor Landscape

**9.1 Competitive scenario

**9.2 Vendor landscape

*Exhibit 35: Vendor Landscape

**9.3 Landscape disruption

*Exhibit 36: Landscape disruption

**9.4 Industry risks

*Exhibit 37: Industry risks

***10. Vendor Analysis

**10.1 Vendors covered

*Exhibit 38: Vendors covered

**10.2 Market positioning of vendors

*Exhibit 39: Market positioning of vendors

*10.3 3M Co.

*Exhibit 40: 3M Co. - Overview

*Exhibit 41: 3M Co. - Business segments

*Exhibit 42: 3M Co. - Key news

*Exhibit 43: 3M Co. - Key offerings

*Exhibit 44: 3M Co. - Segment focus

**10.4 Baxter International Inc.

*Exhibit 45: Baxter International Inc. - Overview

*Exhibit 46: Baxter International Inc. - Business segments

*Exhibit 47: Baxter International Inc. - Key news

*Exhibit 48: Baxter International Inc. - Key offerings

*Exhibit 49: Baxter International Inc. - Segment focus

**10.5 ConvaTec Inc.

*Exhibit 50: ConvaTec Inc. - Overview

*Exhibit 51: ConvaTec Inc. - Product and service

*Exhibit 52: ConvaTec Inc. - Key offerings

*10.6 Dr. Reddys Laboratories Ltd.

*Exhibit 53: Dr. Reddys Laboratories Ltd. - Overview

*Exhibit 54: Dr. Reddys Laboratories Ltd. - Business segments

*Exhibit 55: Dr. Reddys Laboratories Ltd. - Key news

*Exhibit 56: Dr. Reddys Laboratories Ltd. - Key offerings

*Exhibit 57: Dr. Reddys Laboratories Ltd. - Segment focus

**10.7 Fresenius SE & Co. KGaA

*Exhibit 58: Fresenius SE & Co. KGaA - Overview

*Exhibit 59: Fresenius SE & Co. KGaA - Business segments

*Exhibit 60: Fresenius SE & Co. KGaA - Key news

*Exhibit 61: Fresenius SE & Co. KGaA - Key offerings

*Exhibit 62: Fresenius SE & Co. KGaA - Segment focus

**10.8 GlaxoSmithKline Plc

*Exhibit 63: GlaxoSmithKline Plc - Overview

*Exhibit 64: GlaxoSmithKline Plc - Business segments

*Exhibit 65: GlaxoSmithKline Plc - Key news

*Exhibit 66: GlaxoSmithKline Plc - Key offerings

*Exhibit 67: GlaxoSmithKline Plc - Segment focus

**10.9 Merck & Co. Inc.

*Exhibit 68: Merck & Co. Inc. - Overview

*Exhibit 69: Merck & Co. Inc. - Business segments

*Exhibit 70: Merck & Co. Inc. - Key news

*Exhibit 71: Merck & Co. Inc. - Key offerings

*Exhibit 72: Merck & Co. Inc. - Segment focus

**10.10 Mylan NV

*Exhibit 73: Mylan NV - Overview

*Exhibit 74: Mylan NV - Business segments

*Exhibit 75: Mylan NV - Key news

*Exhibit 76: Mylan NV - Key offerings

*Exhibit 77: Mylan NV - Segment focus

**10.11 Pfizer Inc.

*Exhibit 78: Pfizer Inc. - Overview

*Exhibit 79: Pfizer Inc. - Business segments

*Exhibit 80: Pfizer Inc. - Key news

*Exhibit 81: Pfizer Inc. - Key offerings

*Exhibit 82: Pfizer Inc. - Segment focus

**10.12 Smith & Nephew Plc

*Exhibit 83: Smith & Nephew Plc - Overview

*Exhibit 84: Smith & Nephew Plc - Business segments

*Exhibit 85: Smith & Nephew Plc - Key news

*Exhibit 86: Smith & Nephew Plc - Key offerings

*Exhibit 87: Smith & Nephew Plc - Segment focus

***11. Appendix

**11.1 Scope of the report

*11.1.1 ????Market definition

*11.1.2 ????Objectives

*11.1.3 ????Notes and caveats

**11.2 Currency conversion rates for US$

*Exhibit 88: ?Currency conversion rates for US$?

**11.3 Research Methodology

*Exhibit 89: ?Research Methodology

*Exhibit 90: ??Validation techniques employed for market sizing?

*Exhibit 91: ??Information sources

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

diabetic foot ulcers therapeutics market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis